Bayesian Reanalysis of Adjuvant Nivolumab in Japanese Patients With High-Risk Muscle-Invasive Urothelial Carcinoma.
0/5 보강
APA
Yasuda Y, Yoshida S, et al. (2026). Bayesian Reanalysis of Adjuvant Nivolumab in Japanese Patients With High-Risk Muscle-Invasive Urothelial Carcinoma.. International journal of urology : official journal of the Japanese Urological Association, 33(1), e70305. https://doi.org/10.1111/iju.70305
MLA
Yasuda Y, et al.. "Bayesian Reanalysis of Adjuvant Nivolumab in Japanese Patients With High-Risk Muscle-Invasive Urothelial Carcinoma.." International journal of urology : official journal of the Japanese Urological Association, vol. 33, no. 1, 2026, pp. e70305.
PMID
41339714 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.
- Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.
- Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.
- Successful Rechallenge of Trastuzumab Deruxtecan Following Early Detection of ILD in a Patient with Non-small Cell Lung Carcinoma Harboring HER2 Exon 20 Insertion.
- Restricted mean survival time comparison of olaparib plus abiraterone versus talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer: indirect analyses of propel and talapro-2.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis.
- Estimating the prevalence of germline mutations in DNA mismatch repair genes among patients with upper tract urothelial carcinoma: a systematic review and meta-analysis.
- First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma-commentary on patient-reported outcomes in EV-302.
- Causal links between gut microbiota, metabolites, and diffuse large B-cell lymphoma: Evidence from a Mendelian randomization study.
- SJS/TEN following therapy with pembrolizumab and enfortumab vedotin in a patient with urothelial carcinoma.
- Association between elevated PRIM1 expression and poor prognosis in human urothelial carcinoma.